Tumor vasculature: the Achilles' heel of cancer?

Bibliography

• Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009;19:310-17
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70
   PubMed Web of Science ®Google Scholar
• Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010;10:138-46
   PubMed Web of Science ®Google Scholar
• Kirschmann DA, Seftor EA, Hardy KM, Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18(10):2726-32
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG. Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget 2012;3:98-106
   PubMed Web of Science ®Google Scholar
• Torsvik A, Bjerkvig R. Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Nagy JA, Chang SH, Shih SC, Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010;36:321-31
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Keunen O, Johansson M, Oudin A, Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011;108:3749-54
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:741-8
   PubMed Web of Science ®Google Scholar
• Shojaei F, Simmons BH, Lee JH, F/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett 2012;320:48-55
   PubMedGoogle Scholar
• Schuster C, Eikesdal HP, Puntervoll H, Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 2012;7:e38364
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Schmid MC, Avraamides CJ, Dippold HC, Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011;19:715-27
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20
   PubMed Web of Science ®Google Scholar
• Ishigami SI, Arii S, Furutani M, Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379-84
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Mohr T, Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999;83:415-23
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Gandini O, Gradilone A, Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 1999;14:1123-7
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310
   PubMed Web of Science ®Google Scholar
• Cao Y, Cao R, Hedlund EM. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 2008;86:785-9
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011;55:261-8
   PubMed Web of Science ®Google Scholar
• Klosowska-Wardega A, Hasumi Y, Burmakin M, Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS ONE 2009;4:e8149
   Google Scholar
• Xue Y, Lim S, Yang Y, PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012;18:100-10
   Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16
   PubMed Web of Science ®Google Scholar
• Mazzieri R, Pucci F, Moi D, Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26
   PubMed Web of Science ®Google Scholar
• Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99:11205-10
   PubMed Web of Science ®Google Scholar
• Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 2012;30:441-4
   Google Scholar
• Metheny-Barlow LJ, Li LY. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res 2003;13:309-17
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103
   PubMed Web of Science ®Google Scholar
• Sulpice E, Ding S, Muscatelli-Groux B, Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell 2009;101:525-39
   PubMed Web of Science ®Google Scholar
• Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49
   PubMed Web of Science ®Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23
   PubMed Web of Science ®Google Scholar
• Straume O, Shimamura T, Lampa MJ, Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 2012;109:8699-704
   PubMedGoogle Scholar
• Haslene-Hox H, Oveland E, Berg KC, A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS One 2011;6:e19217
   PubMed Web of Science ®Google Scholar
• Saelen MG, Flatmark K, Folkvord S, Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis 2011;14:481-9
   PubMed Web of Science ®Google Scholar
• Kerbel RS. A cancer therapy resistant to resistance. Nature 1997;390:335-6
   PubMed Web of Science ®Google Scholar
• Maniotis AJ, Folberg R, Hess A, Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52
   PubMed Web of Science ®Google Scholar
• Shen R, Ye Y, Chen L, Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 2008;3:e1652
   PubMedGoogle Scholar
• Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 2009;13:309-19
   PubMed Web of Science ®Google Scholar
• Bussolati B, Bruno S, Grange C, Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008;22:3696-705
   PubMed Web of Science ®Google Scholar
• Alvero AB, Fu HH, Holmberg J, Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009;27:2405-13
   PubMed Web of Science ®Google Scholar
• Wang R, Chadalavada K, Wilshire J, Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3:411-21
   PubMed Web of Science ®Google Scholar
• Fernando NT, Koch M, Rothrock C, Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39
   PubMed Web of Science ®Google Scholar
• Amin DN, Bielenberg DR, Lifshits E, Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 2008;76:15-22
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• Alfranca A, Lopez-Oliva JM, Genis L, PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 2008;112:1120-8
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
   PubMed Web of Science ®Google Scholar
• Miller KD, Sweeney CJ, Sledge GWJ. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 2003;14:20-8
   PubMedGoogle Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;10:6367S-70S
   Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V, Genes expressed in human tumor endothelium. Science 2000;289:1197-202
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Sugimoto H, Birrane G, Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor therapy. Proc Natl Acad Sci USA 2008;105:15040-5
   PubMed Web of Science ®Google Scholar
• Graeber TG, Osmanian C, Jacks T, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91
   PubMed Web of Science ®Google Scholar
• Yu JL, Rak JW, Coomber BL, Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-14
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Cooke VG, LeBleu VS, Keskin D, Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21:66-81
   PubMed Web of Science ®Google Scholar
• Arnold D, Andre T, Bennouna J, Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012;30(Suppl):CRA3503
   Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48
   PubMed Web of Science ®Google Scholar
• Purhonen S, Palm J, Rossi D, Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008;105(18):6620-5
   PubMed Web of Science ®Google Scholar
• Rajantie I, Ilmonen M, Alminaite A, Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004;104:2084-6
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201
   PubMed Web of Science ®Google Scholar
• Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008;13:6537-53
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xavier R, Sugiura T, Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Bray K, Mathew R, Lau A, Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One 2012;7:e41831
   PubMed Web of Science ®Google Scholar
• Sund M, Nyberg P, Eikesdal HP. Endogenous matrix-derived inhibitors of angiogenesis. Pharmaceuticals 2010;3:3021-39
   Google Scholar
• Pircher A, Hilbe W, Heidegger I, Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci 2011;12:7077-99
   PubMed Web of Science ®Google Scholar
• Vermeulen PB, Gasparini G, Fox SB, Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-79
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001;47:617-23
   PubMed Web of Science ®Google Scholar
• Duda DG, Willett CG, Ancukiewicz M, Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010;15:577-83
   PubMedGoogle Scholar
• Tomita Y, Uemura H, Fujimoto H, Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011;47:2592-602
   PubMed Web of Science ®Google Scholar
• An SJ, Huang YS, Chen ZH, Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 2011;29(2):627-32
   PubMedGoogle Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Koutras AK, Antonacopoulou AG, Eleftheraki AG, Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Lambrechts D, Claes B, Delmar P, VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13(7):724-33
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Galizia E, Chiorrini S, Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-30
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73
   PubMed Web of Science ®Google Scholar
• Schuster C, Eikesdal HP, Puntervoll H, Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of early induced hypertension in a single-arm phase II study. PLoS One 2012;7:e38364
   PubMed Web of Science ®Google Scholar
• Rini BI, Grunwald V, Fishman MN, Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012;30(Suppl):abstract 4503
   Google Scholar
• van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-5
   PubMed Web of Science ®Google Scholar
• Brooks PC, Montgomery AM, Rosenfeld M, Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64
   PubMed Web of Science ®Google Scholar
• Schnell O, Krebs B, Wagner E, Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008;18:378-86
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Barnes LA, Shields DJ, An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009;15:1163-9
   PubMed Web of Science ®Google Scholar
• Nisato RE, Tille JC, Jonczyk A, Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003;6:105-19
   PubMedGoogle Scholar
• MacDonald TJ, Taga T, Shimada H, Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001;48:151-7
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B, Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712-18
   PubMed Web of Science ®Google Scholar
• Dumont DJ, Jussila L, Taipale J, Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9
   PubMed Web of Science ®Google Scholar
• Kaipainen A, Korhonen J, Mustonen T, Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995;92:3566-70
   PubMed Web of Science ®Google Scholar
• Partanen TA, Arola J, Saaristo A, VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000;14:2087-96
   PubMed Web of Science ®Google Scholar
• Valtola R, Salven P, Heikkila P, VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-90
   PubMed Web of Science ®Google Scholar
• Paavonen K, Puolakkainen P, Jussila L, Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 2000;156:1499-504
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Wallgard E, Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454:656-60
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Waltari M, Holopainen T, Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007;67:593-9
   PubMed Web of Science ®Google Scholar
• Kubo H, Fujiwara T, Jussila L, Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000;96:546-53
   PubMedGoogle Scholar
• Hori K, Suzuki M, Tanda S, Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 1990;81:279-88
   PubMedGoogle Scholar
• Gerhardt H, Golding M, Fruttiger M, VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-77
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Phng LK, Hofmann JJ, Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80
   PubMed Web of Science ®Google Scholar
• Nicoli S, Knyphausen CP, Zhu LJ, miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell 2012;22:418-29
   Google Scholar
• Biyashev D, Veliceasa D, Topczewski J, miR-27b controls venous specification and tip cell fate. Blood 2012;119:2679-87
   PubMed Web of Science ®Google Scholar
• Fantin A, Vieira JM, Gestri G, Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010;116:829-40
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Nurmi H, VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol 2011;13:1202-13
   PubMed Web of Science ®Google Scholar
• Peinado H, Aleckovic M, Lavotshkin S, Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18(6):883-91
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
   PubMed Web of Science ®Google Scholar
• Lu KV, Chang JP, Parachoniak CA, VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21-35
   PubMed Web of Science ®Google Scholar
• Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002;62:5580-9
   PubMed Web of Science ®Google Scholar
• Sudhakar A, Sugimoto H, Yang C, Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71
   PubMed Web of Science ®Google Scholar
• Kim YM, Hwang S, Pyun BJ, Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9
   PubMed Web of Science ®Google Scholar